An additional perspective and consideration of the implications of the Myriad Genetics case. The article brings several questions to mind, including how far the Supreme Court’s decision might reach and whether and what other medical and technological advances might feel repercussions.
Interesting article. But I wonder whether the issue is the restrictions placed upon patenting genetic material, as opposed to the many other challenges (some of which the author mentions) that the diagnostics industry is facing? To be honest, when I read this, my thought was, “Yes, these are important issues, or possibly even ridiculous hurdles that these companies have to deal with. But none of them are SOLVED by allowing companies to obtain a patent on the actual sequenced DNA that they obtain from human beings.”
Thoughts?